Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bexagliflozin (EGT1442) 是一种选择性的,口服有效的钠葡萄糖协同转运蛋白-2 (SGLT2) 抑制剂,对人 SGLT2 和 SGLT1 作用的 IC50值分别为 2 nM 和 5.6 μM。EGT1442在 2 型糖尿病中有研究价值。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 477 | 现货 | ||
2 mg | ¥ 690 | 现货 | ||
5 mg | ¥ 987 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 3,380 | 现货 | ||
50 mg | ¥ 4,920 | 现货 | ||
100 mg | ¥ 6,880 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,110 | 现货 |
产品描述 | Bexagliflozin (EGT1442) is a potent, selective sodium glucose co-transporter 2 (SGLT2) inhibitor with IC50 values of 5.6 μM and 2 nM for human SGLT1 and SGLT2, respectively |
体内活性 | EGT1442 produces a stable urinary excretion of glucose in rats and dogs with ED50 values of 0.38 and 0.09 mg/kg, respectively, and reduces HbA(1c) and blood glucose in db/db mice in a concentration dependent manner. |
动物实验 | Prior to experiment initiation, 7-week old SHRSP rats were assigned to 3 groups of 15 males each, based on body weights. During this week, daily water consumption was determined in order to calculate appropriate drug concentrations for the drinking water. The following week (Day 1), rats were switched to a stroke-promoting diet containing reduced potassium and protein and elevated NaCl. Animals received water bottles containing either no compound, EGT1442 (3.0 mg/kg) or the sodium channel blocker amiloride (1.0 mg/kg). Body weights were measured 2 times per week, and dosages were adjusted weekly. Water consumption was likewise measured 2 times per week, while food consumption wasmeasured weekly. Daily values were estimated. Urine samples were analyzed by test strips once every two weeks. Additionally, all animals were observed twice daily and any abnormal findings were recorded. |
别名 | THR-1442, EGT1442, EGT0001442 |
分子量 | 464.94 |
分子式 | C24H29ClO7 |
CAS No. | 1118567-05-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (215.08 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1508 mL | 10.7541 mL | 21.5082 mL | 53.7704 mL |
5 mM | 0.4302 mL | 2.1508 mL | 4.3016 mL | 10.7541 mL | |
10 mM | 0.2151 mL | 1.0754 mL | 2.1508 mL | 5.377 mL | |
20 mM | 0.1075 mL | 0.5377 mL | 1.0754 mL | 2.6885 mL | |
50 mM | 0.043 mL | 0.2151 mL | 0.4302 mL | 1.0754 mL | |
100 mM | 0.0215 mL | 0.1075 mL | 0.2151 mL | 0.5377 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bexagliflozin 1118567-05-7 GPCR/G Protein SGLT THR-1442 EGT-1442 EGT 0001442 THR 1442 EGT-0001442 EGT1442 THR1442 EGT 1442 EGT0001442 Inhibitor inhibitor inhibit